Lunsumio (mosunetuzumab-axgb)

Mosunetuzumab demonstrated dose-dependent peripheral B-cell depletion and a safety profile consistent with prior studies in follicular lymphoma. Based on these data, mosunetuzumab is currently being evaluated in a phase II study in severe SLE (NCT07598396).

This study offers real-world evidence for guiding the clinical use of mosunetuzumab. It highlights the necessity for clinicians to monitor for AEs during treatment by recognizing potential adverse reaction signals beyond those documented in the current prescribing information.

P2, N=138, Not yet recruiting, SWOG Cancer Research Network

P2, N=80, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting

P1, N=137, Recruiting, Hoffmann-La Roche | Trial completion date: Feb 2030 --> Feb 2032 | Trial primary completion date: May 2028 --> Feb 2031

P2, N=320, Active, not recruiting, Genentech, Inc. | Trial completion date: Jul 2028 --> Jul 2027 | Trial primary completion date: Jul 2028 --> Jul 2027

P1, N=9, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | N=15 --> 9

The effectiveness of this drug is confirmed in our center.

P2, N=23, Recruiting, Abramson Cancer Center at Penn Medicine | N=42 --> 23

A 74-year-old woman with a history of FL, initially treated with R-CHOP and later with rituximab monotherapy, presented with progressive dyspnea and was found to have bilateral pleural effusion. This case suggests that mosunetuzumab may exert rapid antitumor activity in both systemic disease and malignant effusions, possibly through distribution into pleural fluid and subsequent T-cell-mediated cytotoxicity. Further studies are warranted to clarify the role of bispecific antibodies in malignant effusions associated with lymphoma.

P2, N=30, Recruiting, Hoffmann-La Roche

P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027